From: Designer nucleases to treat malignant cancers driven by viral oncogenes
Etiological agent | Malignancies and other disorders | Targeted and potential oncogenes | Review reference |
---|---|---|---|
HPV | Cervical cancer Oropharyngeal cancer Vagina cancer Penile cancer Anal cancer Vulvar cancer | E6a E7a | |
HTLV-1 | Adult T-cell leukemia/lymphoma (ATL) HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) | HBZ RNA HBZ protein | [14] |
EBV (HHV-4) | Burkitt’s lymphoma (BL) Hodgkin’s lymphoma (HL) Diffuse large B cell lymphoma (DLBCL) NK/T cell lymphoma Post-transplant lymphoproliferative disorders (PTLD) Nasopharyngeal carcinoma (NPC) Gastric carcinoma (GC) | Latent coding  EBNA1a  EBNA2  EBNA3A  EBNA3C  LMP1a  LMP2Aa Latent non-coding  EBERs  EBV miRNAsa | |
KSHV (HHV-8) | Kaposi's sarcoma (KS) Primary effusion lymphoma (PEL) Multicentric Castleman disease (MCD) | Latent coding  LANAa  Kaposin  Viral cyclin (vCyclin)  Viral FLIP (vFLIP) Latent non-coding  K12-miRNAsa | |
MCPyV | Merkel cell carcinoma (MCC) | Large antigen (LT)a Small antigen (sT)a | [19] |